By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Vertex Pharmaceuticals Incorporated 

130 Waverly Street

Cambridge  Massachusetts  02139-4242  U.S.A.
Phone: 617-444-6100 Fax: 617-444-6680


SEARCH JOBS




The Science of Possibility.

The first thing you’ll notice about Vertex is that we are not a conventional pharmaceutical company. Each and every person at Vertex is driven by a passion for fearless innovation and a bold desire to transform the lives of millions with new medicines. Together, by creating new possibilities in medicine, our employees are quite literally changing the world.

Vertex scientists and our collaborators are working on new medicines to advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases. Our development pipeline includes several investigational drugs that have the potential to transform the treatment of serious diseases. Every day brings us a step closer to getting patients the medicines they need and potentially changing their lives in previously unimaginable ways. It’s a demanding yet incredibly rewarding experience that cannot help but change your life in the process, too.

We employ more than 2,000 of the industry’s best and brightest people at locations around the world – all of us working toward tomorrow’s breakthrough medicines.

For more information on Vertex, please visit www.vrtx.com. For information on career opportunities with Vertex, please visit www.careers.vrtx.com..

Key Contacts:
Media: mediainfo@vrtx.com
Investors: investorinfo@vrtx.com
Patient Inquiries: clinical_trials@vrtx.com


This div will be replaced


Key Statistics


Email:
Ownership: Public

Web Site: Vertex Pharmaceuticals (MA)
Employees: ~1000
Symbol: VRTX
 





Collaborations

Cystic Fibrosis Foundation Therapeutics, Inc.  (VX-770 for CF)

Kissei Pharmaceutical Co., Ltd.  (VX-702 for RA)

GlaxoSmithKline  (VX-409 and Backup Compounds)

Janssen Pharmaceutica N.V.  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Merck & Co.  (MK-0457 (VX-680), MK-6592 (VX-667) and VX-689 for Cancer)

Mitsubishi Pharma Corporation  (telaprevir for HCV) - Japan and certain Far East countries





Company News
Vertex Pharmaceuticals (MA) (VRTX) To Present At Deutsche Bank (DB) BioFEST On December 2 11/21/2014 12:37:31 PM
Biotech Investors Bullish On Large Cap; Citi Adds Vertex Pharmaceuticals (MA) (VRTX), BioMarin Pharmaceutical Inc. (BMRN) and Tesaro, Inc. (TSRO) To Most Preferred 11/14/2014 3:27:58 PM
Vertex Pharmaceuticals (MA) (VRTX) Submits Applications In The U.S. And Europe For Approval Of Lumacaftor In Combination With Ivacaftor For People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation 11/5/2014 10:31:25 AM
Vertex Pharmaceuticals (MA) (VRTX) Surges As FDA Advisory Panel Approves Kalydeco's Label Expansion 10/22/2014 5:35:50 AM
Vertex Pharmaceuticals (MA) (VRTX) To Announce Third Quarter 2014 Financial Results On October 28 10/15/2014 9:01:10 AM
Vertex Pharmaceuticals (MA) (VRTX) Reviews Recent Progress And Announces Upcoming Milestones In The Development Of Multiple Combinations Of Medicines That Target The Underlying Cause Of Cystic Fibrosis 10/9/2014 8:39:35 AM
Vertex Pharmaceuticals (MA) (VRTX) Announces Upcoming Presentations Of Data At North American Cystic Fibrosis Conference - October 9 To 11, 2014 9/8/2014 10:29:23 AM
Lung Biotech ProQR Therapeutics B.V. Files For A $75 Million IPO To Give Vertex Pharmaceuticals (MA) (VRTX) Some Competition 8/15/2014 7:04:08 AM
Vertex Pharmaceuticals (MA) (VRTX) To Stop Selling Once-Upon-A-Time Blockbuster Incivek, Shares Slip 8/12/2014 3:58:39 PM
Vertex Pharmaceuticals (MA) (VRTX)'s $300,000 A Year Drug Is Denied, And Medicaid Patients Sue 7/18/2014 7:42:11 AM
12345678910...
//-->